Compared to Estimates, Conmed (CNMD) Q3 Earnings: A Look at Key Metrics

Core Insights - Conmed reported revenue of $337.93 million for the quarter ended September 2025, reflecting a year-over-year increase of 6.7% and exceeding the Zacks Consensus Estimate of $336.52 million by 0.42% [1] - The company's EPS for the quarter was $1.08, up from $1.05 in the same quarter last year, resulting in an EPS surprise of 2.86% compared to the consensus estimate of $1.05 [1] Revenue Breakdown - International revenue reached $143.9 million, a 7.8% increase year-over-year, but below the average estimate of $148.63 million [4] - Domestic revenue was reported at $194 million, surpassing the average estimate of $187.89 million, with a year-over-year growth of 5.9% [4] - Net sales for single-use products totaled $289.2 million, slightly above the average estimate of $288.97 million, marking a 6.8% increase year-over-year [4] - General surgery net sales were $199.7 million, close to the average estimate of $200.27 million, reflecting a 7.3% year-over-year change [4] - Orthopedic surgery net sales amounted to $138.2 million, exceeding the average estimate of $136.24 million, with a year-over-year increase of 5.9% [4] - Capital products net sales were reported at $48.7 million, above the average estimate of $47.55 million, showing a 6.1% increase compared to the previous year [4] Stock Performance - Conmed's shares have returned -0.4% over the past month, while the Zacks S&P 500 composite has increased by 1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]